Biotech is an industry defined by splashy startups pitching groundbreaking, life-changing treatments — if only they had a bit more money to test them. But unless those companies eventually go public, finding out exactly what’s going on behind the scenes can be tricky. For outsiders, sporadic press releases may contain the only clues, even as companies continue to pull in venture funding or other investments.

Those press releases often make big promises — but there’s rarely any follow-up. As part of our quarterly Something Ventured series, STAT took a look at four companies that closed an early-stage venture round between January and March of last year. We looked back at what they promised to do with all that capital — and what they’ve actually done with it.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Nice. Looks like a free, interesting, informative service but NOOOOOO…..I HAVE TO PAY. FORGET IT. I’m going back to Fierce, and you can FORGET IT.
    No, this isn’t a duplicate comment!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy